- Global Pharma News & Resources

Hologic to Showcase Growing Portfolio of Breast and Skeletal Health Innovations at RSNA 2018

Hologic, Inc. (Nasdaq: HOLX) will showcase its expanding suite of breast and skeletal health products, including screening, interventional, ultrasound and surgical solutions, in Booth #2511 at the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Nov. 25 to 29.

The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has expanded significantly in recent years to offer innovations across the entire clinical continuum of breast health. These new products range from the SmartCurve™ breast stabilization system and Clarity HD high-resolution 3D™ imaging technology, to the Viera™ portable breast ultrasound and Brevera® breast biopsy system with CorLumina® imaging technology, which features real-time imaging and sample verification. In addition, two recent acquisitions of Faxitron® Bioptics, a leader in digital specimen radiography, and Focal Therapeutics, manufacturer of the BioZorb® marker, have enabled Hologic to play a larger role in breast conserving surgery and strengthened its offerings to radiologists, pathologists and breast surgeons.

“As a world leader in mammography, we have built our breast and skeletal health division on a foundation of breakthrough solutions proven to improve cancer detection, patient satisfaction and facility workflow, and reduce costs associated with unnecessary callbacks,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “We have spent the past several years thoughtfully expanding this portfolio through a commitment to insight-driven innovation and strategic acquisitions that align with our mission. Now we can make a positive impact on breast health at each step of a patient’s journey – from screening to pathology. We look forward to using our time at RSNA to highlight how Hologic plans to continue to lead the industry forward as the partner of choice to meet the increasing number of unmet and changing needs of our customers and their patients.”

During the show, Hologic will host a number of workshops and a CME symposium, Contrast Enhanced Mammography: Incorporating CEM Into Your Clinical Practice, led by Bhavika Patel, MD and Chief, Breast Imaging Section, Department of Radiology, Mayo Clinic. Workshops will focus on a variety of topics including synthesized 2D imaging technology, real-time breast specimen imaging, breast density assessment and screening, tomosynthesis-guided prone biopsy solutions, and a clinical perspective on implementing the Genius exam and SmartCurve system. In addition, interactive booth highlights will include:

  • The Breast Biopsy Innovation Suite, featuring Hologic’s complete range of biopsy solutions designed to deliver improved patient satisfaction, better clinician workflow, and facility cost savings. Visitors to the suite can participate in hands-on demonstrations of LOCalizer™, Hologic’s new wireless radiofrequency identification (RFID) breast lesion localization system, and the Viera™ portable breast ultrasound system.
  • An A.I. Future Suite highlighting Hologic’s longstanding commitment to incorporating artificial intelligence and machine learning into its groundbreaking technologies. Attendees will experience current and future applications of A.I. in breast imaging, and learn more about how Hologic plans to continue delivering significant value as a leader in the space.
  • The opportunity to take the Clarity Challenge to identify cases featuring Hologic’s new Clarity HD high-resolution 3D™ imaging technology. This technology provides the industry's fastest, highest resolution 3D™ images to accelerate screening and analysis, and is designed to clearly reveal subtle lesions and fine calcifications to help pinpoint cancers early. Attendees will be encouraged to review cases displayed on multiple workstations to determine which were obtained using this new technology, and view the challenge results in real-time.

Visitors to Hologic’s booth also will have access to the Company’s entire suite of breast and skeletal health products, including a number of new innovations that were introduced earlier this year, such as the 3Dimensions™ Mammography System and Fluoroscan® Insight™ FD Mini C-Arm. The 3Dimensions system, the fastest, highest resolution breast tomosynthesis system to date, provides higher resolution 3D™ images for radiologists, enhanced workflow for technologists, and a more comfortable mammography experience, with low-dose options, for patients.1 The enhanced Fluoroscan system adds to Hologic’s portfolio of market-leading skeletal imaging solutions. It offers a variety of improved features designed to arm orthopedists, podiatrists and clinicians with diversified imaging options, more flexible storage and transport, and an enhanced interface.

RSNA is an international society of radiologists, medical physicists and other medical professionals with 55,000 members from more than 140 countries. The RSNA Annual Meeting is expected to attract more than 60,000 attendees. For more information or to RSVP for a workshop or symposium, please visit or stop by the Hologic booth #2511 or Faxitron booth #1916.

The Genius™3D Mammography™exam (also known as the Genius™ exam) is only available on a Hologic®3D Mammography™system. It consists of a 2D and 3D™image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™image set. There are more than 5,000 Hologic 3D Mammography™ systems in use in the U.S. alone, so women have convenient access to the Genius exam. To learn more about the Genius exam, visit

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit

Hologic, 3D, 3D Mammography, 3Dimensions, Biozorb, Brevera, CorLumina, Faxitron, Fluoroscan, Focal Therapeutics, Genius, Insight, LOCalizer, SmartCurve, The Science of Sure and Viera are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to

1 Data on file

SOURCE: Hologic, Inc.

View source version on

Editor Details

Last Updated: 23-Nov-2018